MA42654A - Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt - Google Patents

Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt

Info

Publication number
MA42654A
MA42654A MA042654A MA42654A MA42654A MA 42654 A MA42654 A MA 42654A MA 042654 A MA042654 A MA 042654A MA 42654 A MA42654 A MA 42654A MA 42654 A MA42654 A MA 42654A
Authority
MA
Morocco
Prior art keywords
pyridin
acrylamide
nampt
pak
modulators
Prior art date
Application number
MA042654A
Other languages
English (en)
Inventor
Erkan Baloglu
William Senapedis
Sharon Shacham
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of MA42654A publication Critical patent/MA42654A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA042654A 2015-08-17 2016-08-17 Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt MA42654A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562205964P 2015-08-17 2015-08-17

Publications (1)

Publication Number Publication Date
MA42654A true MA42654A (fr) 2018-06-27

Family

ID=56799625

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042654A MA42654A (fr) 2015-08-17 2016-08-17 Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt

Country Status (4)

Country Link
US (1) US20190218207A1 (fr)
EP (1) EP3337796A1 (fr)
MA (1) MA42654A (fr)
WO (1) WO2017031213A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3016946T3 (da) 2013-07-03 2023-01-09 Karyopharm Therapeutics Inc Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
WO2017031323A1 (fr) 2015-08-18 2017-02-23 Karyopharm Therapeutics Inc. (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-méthylpyrrolidine-1-carbonyl)phényl)-7-(4-fluorophényl)benzofuran-2-yl)méthyl) acrylamide pour le traitement du cancer
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
WO2018191747A1 (fr) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et procédés pour le traitement de l'hypertension pulmonaire
CN110945128B (zh) * 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 用于治疗肺纤维化的组合物和方法
WO2019036024A1 (fr) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company Dérivés de 2-(1,1'-biphényl)-1h-benzo[d]imidazole et composés apparentés en tant qu'agonistes d'apéline et d'apj pour le traitement de maladies cardiovasculaires
CN111205232B (zh) * 2020-02-26 2022-07-01 浙江天宇药业股份有限公司 一种替格瑞洛中间体的合成方法
CN117624088A (zh) * 2023-12-06 2024-03-01 中科国生(杭州)科技有限公司 一种氢化制备2,5-呋喃二甲胺的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3016946T3 (da) * 2013-07-03 2023-01-09 Karyopharm Therapeutics Inc Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
US9994558B2 (en) * 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same

Also Published As

Publication number Publication date
WO2017031213A1 (fr) 2017-02-23
US20190218207A1 (en) 2019-07-18
EP3337796A1 (fr) 2018-06-27

Similar Documents

Publication Publication Date Title
MA42654A (fr) Dérivés 3-(pyridin-3-yl)-acrylamide et n-(pyridin-3-yl)-acrylamide et leur utilisation comme modulateurs de pak ou nampt
IL283582A (en) Modulators of ror-gamma
EP3490565A4 (fr) Modulateurs de récepteurs de chimiokine et leurs utilisations
MA50014A (fr) Modulateurs de k-ras
MA43251A (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA43382A (fr) Modulateurs des récepteurs des chimiokines
LT3440076T (lt) Heterocikliniai amidai, naudingi kaip baltymų moduliatoriai
MA44075A (fr) Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
EP3356381A4 (fr) Dérivés nucléotidiques et leurs méthodes d'utilisation
MA55328A (fr) Modulateurs de ror-gamma
DK3331876T3 (da) Modulators of ror-gamma
DK3490986T3 (da) Piperidin-cxcr7-receptormodulatorer
PT3160964T (pt) Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos
FR3021533B1 (fr) Composition cosmetique de type gel
EP3450460A4 (fr) Conjugué de liaison multi-spécifique, compositions pharmaceutiques associées et utilisation
PT3426251T (pt) Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2
DK3359160T3 (da) Farnesoid x receptor modulatorer
LT3294713T (lt) Pakeisti tetrahidrokvinoliniai junginiai, kaip ror gama moduliatoriai
LT3319963T (lt) Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
EP3580223A4 (fr) Modulateurs du récepteur des strogènes de benzothiophène
EP3654987A4 (fr) Utilisation de dérivés aminoalkylbenzothiazépine
MA40759A (fr) Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
IL255185A0 (en) 1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
HUE061759T2 (hu) Komplement aktivitás modulátorai
EP3353303A4 (fr) Compositions et méthodes de modulation de l'expression de l'ataxine 3